The label expansion means risdiplam is approved for spinal muscular atrophy for all ages. The FDA this week approved an expanded indication for risdiplam (Evrysdi) to include the treatment of ...
Researchers compiled data from studies of oral Evrysdi (risdiplam), Spinraza (nusinersen), and Zolgensma (onasemnogene abeparvovec), finding evidence that risdiplam may be a favorable alternative to ...
Roche’s risdiplam has come through another late-phase test, triggering improvements in the motor skills of infants with type 1 spinal muscular atrophy (SMA). The clinical success comes months before ...
SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Daily treatment with risdiplam over 24 months resulted ...
The first prenatal treatment for spinal muscular atrophy showed promise in a single case report. Risdiplam was given to the mother during pregnancy and to the child after birth. More than 2 years ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating ...
Living with a degenerative disability is difficult, but it's nothing compared to knowing there are life-changing treatments I can't access because I'm too old, and they are too expensive. I have ...
The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers for full ...
SOUTH PLAINFIELD, N.J., Oct. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency ...
Safety in SUNFISH and JEWELFISH was consistent with the safety profile observed to date and no new safety signals were identified Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results